Clinical trials: Infections, Coronavirus
Pneumonia
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin…
- Trial name
- RECOVERY (NCT04381936)
- Testing
- Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine
- Where
- 16 sites in Belgium, Estonia and 14 more
- Volunteers
- 70,000 people
- Sponsor
- University of Oxford
COVID-19
The Prognostic Factors of COVID-19 ARDS Patients and Their Long-term Follow-up of Pulmonary Function Test
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging infectious disease with high transmissibility. Around 20-25% of infected individuals develop severe COVID-19 disease requiring hospitalization and…
- Trial name
- NCT05490914
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID-19
To Evaluate SSD8432/Ritonavir in Adults With COVID-19
This is a randomized, double-blind, placebo-controlled, phase II/III clinical study to evaluate the efficacy and safety of SSD8432 in combination with ritonavir in adult subjects with mild/common COVID-19.
- Trial name
- NCT05373433
- Testing
- SSD8432 750mg
- Volunteers
- 670 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
COVID-19
Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation
This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who require supplemental oxygen.
- Trial name
- NCT04456452
- Testing
- Ampion, Standard of Care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ampio Pharmaceuticals. Inc.
SARS-CoV 2
Exploring Brain Damages After COVID-19 Infection
Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS).
- Trial name
- BRAINCOV (NCT04405986)
- Testing
- Auditory Evoked Potentials (AEP), Blink and Masseter Inhibitory Reflex
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Asthenia, COVID-19
Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19
to assess executive network using resting-state fMRI and patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking the drug in comparison with placebo in patients with post-COVID…
- Conditions
- Asthenia, COVID-19, Functional MRI, Cognitive Impairment
- Trial name
- NCT05939622
- Testing
- Structural and functional MRI, Ethyl methyl hydroxypyridine succinate + Meldonium
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Promomed, LLC
COVID-19
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04756323
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Covid19
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high…
- Trial name
- NCT04840459
- Testing
- BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sohail Rao
Psychological Distress, Quality of Life
The Effectiveness of Culturally Adapted Cognitive Behavioral Intervention Among COVID-19 Survivors
The effectiveness study for Culturally-Adapted Cognitive Behavioral Intervention (CA-CBI) will be conducted with individuals infected with and recovered from Coronavirus disease (COVID-19) to measure if this intervention is…
- Conditions
- Psychological Distress, Quality of Life, Depressive Symptoms, Anxiety
- Trial name
- NCT04949061
- Testing
- Culturally Adapted Cognitive Behavioral Intervention (CA-CBI), Enhanced Treatment as Usual (ETA-U)
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Koç University
Vaccine Refusal, Covid19
Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.
- Trial name
- VaccEffect (NCT05069454)
- Testing
- COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine
- Where
- Azerbaijan
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Public health and reforms Center of Ministry of Health
COVID-19
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in…
- Trial name
- NCT07664696
- Testing
- IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- Volunteers
- 64 people
- Sponsor
- Kimera Labs Inc.
Post-Acute COVID-19 Syndrome, Dysautonomia
Post Covid-19 Dysautonomia Rehabilitation Randomized Controlled Trial
Dysautonomia in post-covid-19 condition appears to affect a significant number of patients, with reports raising the incidence up to 61%, having an overlap with myalgic encephalomyelitis/ chronic fatigue syndrome.
- Trial name
- LoCoDiRe-Dys (NCT05855356)
- Testing
- Rehabilitation, Standard of Care
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Evangelismos Hospital
COVID-19
COVID-19 Pandemic and Worldwide Organ Procurement
End-stage organ failure is estimated to affect more than 4 to 6 million persons worldwide. In 2018, transplant systems across the globe enabled around 150,000 patients to benefit from a kidney, heart, lung, liver, or other solid…
- Trial name
- COVID (NCT04416256)
- Where
- France
- Volunteers
- 230,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Covid19, COVID-19
Tocilizumab in Coronavirus-19 Positive Patients
This is a cohort study of COVID-19 patients with hyperinflammation. It aims to determine the impact of adjunctive Tocilizumab (TCZ) to standard of care on the reduction of hyperinflammation-related mortality in COVID-19.
- Conditions
- Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus
- Trial name
- NCT04423042
- Testing
- Tocilizumab
- Volunteers
- 30 people
- Sponsor
- University of Calgary
Osteoarthritis
COVID-19 in Osteoarthritis Patients
While the coronavirus pandemic has spread rapidly around the world, it has generated a considerable degree of fear, concern and anxiety among the population in general and among certain groups in particular, such as older…
- Trial name
- NCT04791462
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Montpellier
MS (Multiple Sclerosis), COVID-19
SUNLIGHT Study: Online Support Groups for MS to Address COVID-19
Stress and anxiety can have an adverse impact on health, and the experience of many around the 2020 outbreak of COVID-19 is affecting health and well-being.
- Conditions
- MS (Multiple Sclerosis), COVID-19, Support Groups
- Trial name
- NCT04379661
- Testing
- Online support Group
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Columbia University
COVID-19
Trial of 2nd Booster Dose of COVID-19 Vaccine
Background Recent studies indicate that a 2nd booster dose is associated with lower risk of severe COVID-19. The studies are based on Israeli registry data, comparing outcomes among individuals who have taken the booster, or not.
- Trial name
- NCT05539703
- Testing
- Invitation to get a 2nd booster dose of COVID-19 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
COVID-19
Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05082727
- Testing
- KOVIR (TD0068) oral softgel
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Sao Thai Duong Joint Stock Company
Acute Respiratory Distress
The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19
This is a phase II study to test adenosine efficacy for down-regulation of the overwhelming inflammation of COVID-19 in the lungs as reflected by clinical recovery of lung function; resolution of clinically relevant markers of…
- Trial name
- NCT04588441
- Testing
- Adenosine
- Sponsor
- University of Florida
COVID-19
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
- Trial name
- TACKLE (NCT04723394)
- Testing
- AZD7442
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 910 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.